Physician profile
Lea Lund
NPI 1518073550
$3,491.62
in general payments reported to CMS, 2019-2025
28 companies · $618 in 2025
The $618 reported for 2025 was more than what 94% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $501 · 2021: $520 · 2022: $512 · 2023: $582 · 2024: $317 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $706.81 | 2022-2025 | Azstarys |
| Tris Pharma INC | $529.46 | 2019-2023 | Dyanavel Xr |
| Pfizer INC. | $397.65 | 2019-2025 | |
| Neos Therapeutics, Lp | $274.91 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $203.47 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $164.19 | 2021-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $139.33 | 2020-2025 | Rotateq, Vaxneuvance, Gardasil 9 |
| Glaxosmithkline, LLC. | $130.68 | 2019-2025 | Bexsero |
| Adlon Therapeutics L.P. | $127.78 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $115.04 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $90.27 | 2019-2022 | |
| Cranial Technologies, INC | $83.19 | 2019-2023 | Doc Band |
| Acadia Pharmaceuticals INC | $76.97 | 2025 | Daybue |
| Sanofi Pasteur INC. | $76.27 | 2023 | |
| Kaleo, INC. | $66.62 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $54.99 | 2021-2025 | Flucelvax |
| Sanofi-Aventis U.S. LLC | $39.85 | 2025 | |
| Rhodes Pharmaceuticals L.P. | $30.56 | 2019 | |
| Alk-Abello, INC | $23.88 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.81 | 2019 | |
| Sobi, INC | $21.55 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $20.39 | 2022 | |
| Abbott Laboratories | $18.11 | 2025 | Id Now Instrument |
| Qiagen, LLC | $17.44 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.38 | 2025 | Zoryve |
| Cipher Pharmaceuticals US LLC | $15.34 | 2025 | Natroba, Spinosad |
| Alexion Pharmaceuticals, INC. | $14.56 | 2022 | |
| Abbvie INC. | $13.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea Lund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.